These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 22018457)

  • 1. CKD-mineral and bone disorder: core curriculum 2011.
    Moorthi RN; Moe SM
    Am J Kidney Dis; 2011 Dec; 58(6):1022-36. PubMed ID: 22018457
    [No Abstract]   [Full Text] [Related]  

  • 2. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
    Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
    Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
    Koizumi M; Komaba H; Fukagawa M
    Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Control of phosphorus and treatment with vitamin D in chronic kidney disease prior to the start of dialysis].
    Sánchez González MC; Fernandez Giraldez E; Valdivielso Revilla JM
    Nefrologia; 2008; 28 Suppl 5():39-45. PubMed ID: 18847419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic kidney disease: Phosphate binder therapy--cracks in the tower of strength?
    Evenepoel P; Meijers B
    Nat Rev Nephrol; 2012 Nov; 8(11):615-6. PubMed ID: 23045230
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of phosphate binders in moderate CKD.
    Block GA; Wheeler DC; Persky MS; Kestenbaum B; Ketteler M; Spiegel DM; Allison MA; Asplin J; Smits G; Hoofnagle AN; Kooienga L; Thadhani R; Mannstadt M; Wolf M; Chertow GM
    J Am Soc Nephrol; 2012 Aug; 23(8):1407-15. PubMed ID: 22822075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing bone mineral disorders in CKD: an overview of current therapies.
    Delaney M
    J Ren Care; 2009 Mar; 35 Suppl 1():107-10. PubMed ID: 19222741
    [No Abstract]   [Full Text] [Related]  

  • 10. Update on the treatment of chronic kidney disease-mineral and bone disorder.
    Bover J; Farré N; Andrés E; Canal C; Olaya MT; Alonso M; Quílez B; Ballarín J
    J Ren Care; 2009 Mar; 35 Suppl 1():19-27. PubMed ID: 19222727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphate binders in CKD: bad news or good news?
    Drüeke TB; Massy ZA
    J Am Soc Nephrol; 2012 Aug; 23(8):1277-80. PubMed ID: 22797178
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats.
    Nagano N; Miyata S; Abe M; Kobayashi N; Wakita S; Yamashita T; Wada M
    Kidney Int; 2006 Feb; 69(3):531-7. PubMed ID: 16395276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of fibroblast growth factor 23 in chronic kidney disease-mineral and bone disorder.
    Diniz H; Frazão JM
    Nefrologia; 2013 Nov; 33(6):835-44. PubMed ID: 24158124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic Kidney Disease-Mineral Bone Disorder in Korean Patients: a Report from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD).
    Kim CS; Bae EH; Ma SK; Han SH; Lee KB; Lee J; Oh KH; Chae DW; Kim SW;
    J Korean Med Sci; 2017 Feb; 32(2):240-248. PubMed ID: 28049234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology, efficacy and safety of oral phosphate binders.
    Hutchison AJ; Smith CP; Brenchley PE
    Nat Rev Nephrol; 2011 Sep; 7(10):578-89. PubMed ID: 21894188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sevelamer and the bone-vascular axis in chronic kidney disease: bone turnover, inflammation, and calcification regulation.
    Brandenburg VM; Jahnen-Dechent W; Ketteler M
    Kidney Int Suppl; 2009 Dec; (114):S26-33. PubMed ID: 19946324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphate binders in moderate chronic kidney disease: where do we stand?
    Bellasi A; Cozzolino M; Adragao T; Di Iorio B; Russo D
    J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Focus on vitamin D therapy in chronic kidney disease.
    Tentori F
    J Nephrol; 2007; 20(5):511-4. PubMed ID: 17918134
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of sevelamer to examine the role of intraluminal phosphate in the pathogenesis of secondary hyperparathyroidism.
    Phelps KR; Stote KS; Mason D
    Clin Nephrol; 2014 Sep; 82(3):191-201. PubMed ID: 25079864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study.
    Toida T; Fukudome K; Fujimoto S; Yamada K; Sato Y; Chiyotanda S; Kitamura K
    Clin Nephrol; 2012 Sep; 78(3):216-23. PubMed ID: 22874110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.